CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial
November 03, 2014 at 08:33 AM EST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of October the Company enrolled 22 patients with advanced ...